Adetunji T. Toriola, M.D., Ph.D.

Assistant Professor
Public Health Sciences

Human and Statistical Genetics Program
Immunology Program
Molecular Genetics and Genomics Program

  • 314-286-2668

  • 8100


  • Associations of energetics and inflammation with cancer risk and survival

Research Abstract:

Dr. Toriola’s research interest focuses on the use of biomarkers to investigate the associations of energetics, hormones and inflammation with cancer risk and survival. He is especially interested in the interplay between inflammation and insulin resistance in cancer risk and mortality and the translational importance of such relationship. He has taken leading roles in studies conducted within large cohorts such as the Women’s’ Health Initiative Observational Study, Finnish Maternity Cohort, Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and Kuopio Ischemic Heart Disease Risk Factor Study.

Selected Publications:

Toriola AT, Fields R. Inflammatory, insulin resistance metabolic markers and pancreatic cancer: Quo vadis. Future Oncology 2014 (In press).

Ulrich CM, *Rankin C, *Toriola AT, Makar KW, Altug-Teber , Benedetti JK, Holmes RS, Smalley SR, Blanke DS, Lenz H-J. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304). Cancer 2012 (In press). *Equal contribution.

Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, Linehan D, Colditz G. Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer 2014:2014:111(1): 181-5.

Toriola AT, Nguyen N, Scheitler-Ring K, Colditz G. Circulating 25-hydroxyvitamin D (25-OHD) levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomark Prev. 2014:2014:23(6); 917-933.

Toriola AT, Tolockiene E, Schock H, Surcel H-M, Zeleniuch-Jacquotte A, Wadell G, Toniolo P, Lundin E, Grankvist K, Lukanova A. Free beta human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer. Future Oncology Future Oncology 2014:10(3):377-84.

Toriola AT, Laukannen JA, Kurl S, Nyyssonen K, Ronkainen K, Kauhanen J. Pre-diagnostic circulating markers of inflammation and risk of prostate cancer. International Journal of Cancer 2013:133 (12); 2961-7.

Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, Makar KW, Kazanov D, Galazan L, Naumov I, Coghill AE, Duggan D, Gigic B, Arber N, Ulrich CM. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX-2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenetics and genomics 2013;23(8):428-37.

Toriola AT, Cheng T-YD, Neuhouser ML, Wener MH, Zheng Y, Brown E, Miller JW, Song X, Beresford SAA, Gunter MJ, Caudill MA, Ulrich CM. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013:132(11):2648-59.

Ulrich CM, Toriola AT, Koepl LM, Sandifer T, Poole EM, Duggan C, McTiernan A, Issa JP. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics 2012;7(9):1020-1028

Toriola AT, Ulrich CM. Is there a potential use for C-reactive protein as a diagnostic and prognostic marker for colorectal cancer? Future Oncology 2011; 7(10): 1125-8.

Last Updated: 8/5/2014 3:44:00 PM

Back To Top

Follow us: